Cardax, Inc. (CDXI: OTCQB) | Cardax Astaxanthin Compound Chosen for Important NIH Anti-Aging Research Program

Cardax Astaxanthin Compound Chosen for Important NIH Anti-Aging Research Program

Jun 18, 2017

OTC Disclosure News Service

Cardax, Inc. (“Cardax”) (OTCQB:CDXI) and the University of Hawaii (“UH”)
announced today that the National Institute on Aging (“NIA”), one of the
federal government’s National Institutes of Health (“NIH”), has selected
Cardax’s proprietary astaxanthin compound CDX-085 for its anti-aging
Interventions Testing Program (“ITP”). Only 4-5 compounds per year are
typically chosen by the NIA for this program.

This selection resulted from a proposal to the ITP submitted by UH
faculty Bradley Willcox, M.D. and Richard Allsopp, Ph.D. that was given
a “high priority” ranking by the NIA. Dr. Willcox is Professor and
Director of Research at the Department of Geriatric Medicine, John A.
Burns School of Medicine), University of Hawaii (“JABSOM”), Principal
Investigator of the NIH-funded Kuakini Hawaii LIFESPAN and HEALTHSPAN
Studies, and Cardax Scientific Advisory Board member. Dr. Allsopp is an
Associate Professor at the Institute for Biogenesis Research at JABSOM.

Assuming pilot studies to confirm stability in mouse chow and
bioavailability are successful, the NIA would begin studies with CDX-085
in 2018.

The ITP, according to Longevity Magazine, is the most rigorous aging
research program in the U.S. It is funded by the NIA and conducted
through cooperative agreement grants at the University of Michigan, the
University of Texas Health Science Center at San Antonio, and Jackson
Labs. Anti-aging research candidates selected for the NIA program (“ITP
selectees”) are extensively screened and chosen by NIH for their
potential impact on lifespan extension and their ability to delay
disease and dysfunction in mice at different ages. ITP selectees are
sourced from pharmaceuticals, nutraceuticals, foods, diets, dietary
supplements, plant extracts, hormones, peptides, amino acids, chelators,
redox agents, and other agents or mixtures of agents.

The ITP testing protocols provide sufficient statistical power to detect
lifespan changes in the 10–15 percent range. In addition, ITP selectees
are tested to determine if they have effects on a range of late-life
traits, potentially including studies of immune function, hormonal and
metabolic profiles, and behavioral outcomes. Priority consideration is
given to ITP selectees that are easily obtainable, reasonably priced,
and can be delivered in the diet (preferred) or water.

The NIA study would build upon research recently announced by the
University of Hawaii and Cardax demonstrating the ability of CDX-085 to
activate the important anti-aging gene FOXO3 in mice. CDX-085, like the
Company’s first generation dietary supplement, ZanthoSyn™, delivers
astaxanthin to the blood stream with optimal absorption and purity, but
in a more concentrated form, allowing higher doses per capsule and
improved dosing convenience.

“This is a game changer,” said Dr. Willcox. “Through its inclusion in
the federally funded ITP program, CDX-085 has now been elevated to a
select group of compounds that hold the most promise for potential
anti-aging activity—compounds we hope will foster longer and healthier
lives for aging Americans, and others around the world. This builds on a
growing number of success stories for Cardax and CDX-085.” Dr. Willcox
and Dr. Allsopp conducted the CDX-085/FOXO3 study, mentioned above, and
will be working closely with the NIA during testing of CDX-085 through
the ITP.

“We are excited that the NIA has recognized the potential of our
astaxanthin compound CDX-085 in aging,” added David G. Watumull, Cardax
CEO. “Selection by NIA into this important anti-aging research program
underscores the company’s strategic approach. It also highlights the
importance of the science-based business model we share with our retail
partner, General Nutrition Corporation (“GNC”), and will help us extend
the strong ZanthoSyn brand preference we see in Hawaii amongst the GNC
sales staff, consumers, and physicians to other parts of the U.S.”

About Cardax

Cardax devotes substantially all of its efforts to developing and
commercializing safe anti-inflammatory dietary supplements and drugs.
Cardax is initially focusing on astaxanthin, which is a powerful and
safe naturally occurring anti-inflammatory without the side effects of
currently marketed anti-inflammatories. The safety and efficacy of
Cardax’s products have not been directly evaluated in clinical trials or
confirmed by the FDA.

About the National Institute on Aging

The National Institute on Aging (NIA) is one of the federal government’s
27 institutes and centers of the National Institutes of Health (NIH),
and leads a broad scientific effort to understand the nature of aging
and to extend the healthy, active years of life. NIA, the leader in
aging research, is also the primary Federal agency supporting and
conducting Alzheimer’s disease research.

About CDX-085

CDX-085 is Cardax’s patented astaxanthin compound and is designed to
deliver a highly concentrated form of astaxanthin to the bloodstream.
The Company is developing CDX-085 initially as a dietary supplement and
possibly later as an OTC drug. In monkey studies it was nearly 18x
stronger than a leading microalgal astaxanthin dietary supplement.

About ZanthoSyn

ZanthoSyn™ is a physician recommended anti-inflammatory supplement for
health and longevity that features astaxanthin with optimal absorption
and purity. ZanthoSyn is sold online and in Hawaii GNC stores. ZanthoSyn
contains astaxanthin, which is Generally Recognized as Safe (GRAS)
according to FDA regulations.

About Astaxanthin

Astaxanthin is a clinically studied compound with safe anti-inflammatory
activity that supports joint health, cardiovascular health, metabolic
health, liver health, and mental health.*

About FOXO3

FOXO3 is a member of the forkhead family of transcription factors. The
human homolog in C. elegans, daf-16, has profound effects
on longevity (Kenyon et al. A C. elegans mutant that lives twice
as long as wild type. Nature 1993). Scientists led by Dr. Bradley
Willcox MD, member of the Cardax scientific advisory board, discovered a
genetic variant of FOXO3 in humans that is strongly associated with
longevity (Willcox et al. Proc US Natl Acad Sci 2008). This
observation has since been replicated in 20 independent studies. The
protective FOXO3 allele (SNP rs 2802292 – G allele) doubled the odds to
live to 100 and two G alleles (GG genotype) tripled the odds to live to
100. The protective FOXO3 allele is strongly associated with
reduced coronary heart disease mortality (p=0.00004)) and is also
associated with reduced serum inflammatory markers (CRP and
TNF-α) (Willcox et al. Aging Cell 2016; Willcox et al. J
Gerontol Biol Med Sc
i 2017).

Safe Harbor

This release may contain certain forward-looking statements regarding
our prospective performance and strategies within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. We intend such
forward-looking statements to be covered by the safe harbor provisions
for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995, and are including this statement for
purposes of said safe harbor provisions. Forward-looking statements,
which are based on certain assumptions and describe future plans,
strategies, and expectations of our company, are generally identified by
use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,”
“plan,” “project,” “seek,” “strive,” “try,” or future or conditional
verbs such as “could,” “may,” “should,” “will,” “would,” or similar
expressions. Our ability to predict results or the actual effects of our
plans or strategies is inherently uncertain. Accordingly, actual results
may differ materially from anticipated results. Some of the factors that
could cause our actual results to differ from our expectations or
beliefs include, without limitation, the risks discussed from time to
time in our filings with the Securities and Exchange Commission. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this release. Except as
required by applicable law or regulation, we undertake no obligation to
update these forward-looking statements to reflect events or
circumstances that occur after the date on which such statements were
made.

Copyright © 2017 Businesswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Article source: http://www.otcmarkets.com/stock/CDXI/news?id=162364

Leave a Reply

Bunk Beds